User:Mr. Ibrahem/Nivolumab/relatlimab

Nivolumab/relatlimab, sold under the brand name Opdualag, is a combination medication use to treat melanoma. It is used in cases that cannot be treated by surgery alone and have PD-L1 expression of less than 1%. It is given by gradual injection into a vein.

Common side effects include muscle pain, tiredness, rash, itchiness, and diarrhea. Other side effects may include immune-mediated disorders such as pneumonitis and colitis; and infusion reactions. Use during pregnancy may harm the baby. It contains two monoclonal antibodies; nivolumab, a programmed death receptor-1 (PD-1) blocker, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocker.

The combination was approved for medical use in the United States and Europe in 2022. It is not approved in the United Kingdom as of 2022. In the United States it costs about 29,000 USD every 4 weeks as of 2022.